BIOGEN for BIOGEN
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 20, 2023 | $790,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Feb 13, 2024 | $830,000 | Yes |
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| TYLER HANSON | — |
| DANIEL HARDER | — |
| KATHLEEN KONKA | — |
| ALI LAKHANI | — |
Medicare/Medicaid MMM
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program Medicare reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| DANIEL HARDER | — |
| KATHLEEN KONKA | — |
Pharmacy PHA
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARON NICHOLAS BADIDA | — |
| JONATHAN CAUSEY | — |
| DANIEL HARDER | — |
| KATHLEEN KONKA | — |
Taxation/Internal Revenue Code TAX
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovation and Jobs Act Issues related to OECD negotiations on the taxation of global income
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| DANIEL HARDER | — |
Trade (domestic/foreign) TRD
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL HARDER | — |
Budget/Appropriations BUD
Appropriations on mental health and Alzheiner's screening and diagnosis
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| DANIEL HARDER | — |
Copyright/Patent/Trademark CPT
Support stronger IP and exclusivity protections and enforcement in foreign markets
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL HARDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.